Asset profile
UBT251
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-09-29.
Also in development:Chronic Kidney Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
123 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 118 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| UBT251: this drug | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| Retatrutide | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HM15211 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HM15275 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HRS-4729 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| NNC0662-0419 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells |
…and 108 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (7)
January 2027 (1)
April 2027 (2)
June 2027 (1)
What to watch
September 2027 (2)
October 2027 (1)
What to watch
2028 (2)
2029 (1)
March 2029 (1)
What to watch
2030 (1)
July 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.